Overview

Insulin, Neurogenetics and Memory in Alzheimer's Disease

Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and Development
Treatments:
Rosiglitazone